循环miR-1229作为原发性肝细胞癌诊断与预后生物标志物的价值分析  

Value of circulating miR-1229 as a diagnostic and prognostic biomarker for primary hepatocellular carcinoma

作　　者：罗雪娥 周宁 唐宏英[1] Luo Xuee;Zhou Ning;Tang Hongying(Department of Hepatobiliary Surgery,Hunan Provincial People's Hospital,Changsha 410011,China)

机构地区：[1]湖南省人民医院肝胆外科,湖南长沙410011

出　　处：《实用肿瘤杂志》2020年第4期349-354,共6页Journal of Practical Oncology

基　　金：湖南省人民医院青年博士基金(BSJJ201808)。

摘　　要：目的分析循环miR-1229在原发性肝细胞癌(hepatocellular carcinoma,HCC)患者血清中的表达特征,并分析其作为HCC诊断与预后生物标志物的潜在价值。方法收集HCC患者与体检健康者各150例的外周血标本并成功分离血清。采用qRT-PCR检测血清中循环miR-1229的表达水平。分析循环miR-1229的表达水平与HCC临床病理特征的关系。通过受试者工作特征(receiver operating characteristic,ROC)曲线评估循环miR-1229对HCC诊断的敏感度和特异度。通过Kaplan-Meier法绘制生存曲线,并利用Log-rank检验评估循环miR-1229与HCC患者预后的关系。结果 HCC患者血清中循环miR-1229的表达水平高于健康者(P<0.05)。淋巴结转移阳性HCC患者血清中循环miR-1229的表达水平高于淋巴结转移阴性患者(P<0.05)。循环miR-1229的表达水平在淋巴结转移及远处转移方面比较,差异均具有统计学意义(均P<0.05),但在年龄、性别、乙肝表面抗原(hepatitis B surface antigen,HBsAg)、甲胎蛋白(α-fetoprotein,AFP)水平、肿瘤体积、分化程度、TNM分期及巴塞罗那(barcelona-clinic liver cancer,BCLC)分期方面比较,差异均无统计学意义(均P>0.05)。循环miR-1229对HCC及淋巴结转移具有较高的诊断价值,曲线下面积(area under curve,AUC)分别为0.79和0.86,敏感度分别为68.5%和71.9%,特异度分别为77.5%和82.2%(均P<0.05)。高表达循环miR-1229患者5年总体生存率低于低表达循环miR-1229患者(20.0%vs 26.7%,P<0.05)。结论循环miR-1229在HCC中表达上调,并与淋巴结转移及远处转移相关。循环miR-1229对HCC与淋巴结转移具有较高的诊断价值并与预后相关。Objective To analyze the expression of circulating miR-1229 in serum of patients with primary hepatocellular carcinoma(HCC), and to evaluate its value as a diagnostic and prognostic biomarker for HCC. Methods Peripheral blood samples from 150 HCC patients and 150 healthy subjects were collected, and serum was successful obtained from all blood samples. The levels of circulating miR-1229 in serum from all participants were detected by qRT-PCR assay. The relationship between circulating miR-1229 expression and clinicopathological features were analyzed. The receiver operating characteristic(ROC) curve was used to assess the specificity and sensitivity of circulating miR-1229 for HCC diagnosis. Survival curves were plotted by Kaplan-Meier method and a log-rank test was used to assess the relationship between circulating miR-1229 expression and prognosis in HCC patients. Results The levels of circulating miR-1229 in serum from HCC patients were significantly higher than those in serum from healthy subjects, and the levels of circulating miR-1229 in serum from positive lymph node metastasis patients were higher than those in serum from patients with negative lymph node metastasis(both P<0.05). The levels of circulating miR-1229 were significantly different in terms of lymph node metastasis and distant metastasis(both P<0.05), but were not significantly different in terms of age, gender, hepatitis B surface antigen(HBsAg),α-fetoprotein(AFP) level, tumor size, differentiation, TNM staging, and Barcelona-Clinic Liver Cancer(BCLC) staging(all P>0.05). Circulating miR-1229 had a high diagnostic value for HCC and lymph node metastasis, with an area under curve(AUC)of 0.79 and 0.86, a specificity of 68.5% and 71.9%, and a specificity of 77.5% and 82.2%(all P<0.05). The 5-year overall survival rates of patients with high expression of circulating miR-1229 were significantly lower than those of patients with low expression of circulating miR-1229(20.0% vs 26.7%, P<0.05). Conclusions Circulating miR-1229 is up-regulated in HCC

关 键 词：癌 肝细胞/病理学 癌 肝细胞/诊断 微RNAs/血液 基因表达 生物标记 肿瘤 淋巴转移 聚合酶链反应 预后 

分 类 号：R735.7[医药卫生—肿瘤] R730.23[医药卫生—临床医学]